Arcus Biosciences, Inc. Operating Expenses
Arcus Biosciences, Inc. (RCUS) reported Operating Expenses of $137.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- Arcus Biosciences, Inc. operating expenses for the quarter ending 2026-06-30 was $137.00M, a 18.45% decline year-over-year.
- Arcus Biosciences, Inc. operating expenses for the quarter ending 2026-03-31 was $151.00M, a 0.67% increase year-over-year.
- Arcus Biosciences, Inc. operating expenses for the quarter ending 2025-12-31 was $147.00M, a 13.95% increase year-over-year.
- Arcus Biosciences, Inc. operating expenses for the quarter ending 2025-09-30 was $168.00M, a 9.80% increase year-over-year.
- Arcus Biosciences, Inc. operating expenses for fiscal 2025 was $633.00M, a 7.65% increase from fiscal 2024.
- Arcus Biosciences, Inc. operating expenses for fiscal 2024 was $588.00M, a 28.67% increase from fiscal 2023.
- Arcus Biosciences, Inc. operating expenses for fiscal 2023 was $457.00M, a 16.58% increase from fiscal 2022.
- Arcus Biosciences, Inc. operating expenses for fiscal 2022 was $392.00M, a 19.15% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $137.00M 10-Q · filed 2026-08-05 | $288.00M 10-Q · filed 2026-08-05 | $435.00M derived: sum of 3 quarters · filed 2026-08-05 | $603.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $151.00M 10-Q · filed 2026-05-05 | $298.00M derived: sum of 2 quarters · filed 2026-05-05 | $466.00M derived: sum of 3 quarters · filed 2026-05-05 | $634.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $147.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $315.00M derived: sum of 2 quarters · filed 2026-02-25 | $483.00M derived: sum of 3 quarters · filed 2026-08-05 | $633.00M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $168.00M 10-Q · filed 2025-10-28 | $336.00M derived: sum of 2 quarters · filed 2026-08-05 | $486.00M 10-Q · filed 2025-10-28 | $615.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $168.00M 10-Q · filed 2026-08-05 | $318.00M 10-Q · filed 2026-08-05 | $447.00M derived: sum of 3 quarters · filed 2026-08-05 | $600.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $150.00M 10-Q · filed 2026-05-05 | $279.00M derived: sum of 2 quarters · filed 2026-05-05 | $432.00M derived: sum of 3 quarters · filed 2026-05-05 | $577.00M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $129.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $282.00M derived: sum of 2 quarters · filed 2026-02-25 | $427.00M derived: sum of 3 quarters · filed 2026-02-25 | $588.00M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $153.00M 10-Q · filed 2025-10-28 | $298.00M derived: sum of 2 quarters · filed 2025-10-28 | $459.00M 10-Q · filed 2025-10-28 | $581.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | $145.00M 10-Q · filed 2025-08-06 | $306.00M 10-Q · filed 2025-08-06 | $428.00M derived: sum of 3 quarters · filed 2026-02-25 | $540.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | $161.00M 10-Q · filed 2025-05-06 | $283.00M derived: sum of 2 quarters · filed 2026-02-25 | $395.00M derived: sum of 3 quarters · filed 2026-02-25 | $507.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $122.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $234.00M derived: sum of 2 quarters · filed 2026-02-25 | $346.00M derived: sum of 3 quarters · filed 2026-02-25 | $457.00M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | $112.00M 10-Q · filed 2024-11-06 | $224.00M derived: sum of 2 quarters · filed 2024-11-06 | $335.00M 10-Q · filed 2024-11-06 | $443.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | $112.00M 10-Q · filed 2024-08-08 | $223.00M 10-Q · filed 2024-08-08 | $331.00M derived: sum of 3 quarters · filed 2025-02-25 | $434.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | $111.00M 10-Q · filed 2024-05-08 | $219.00M derived: sum of 2 quarters · filed 2025-02-25 | $322.00M derived: sum of 3 quarters · filed 2025-02-25 | $418.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | $108.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $211.00M derived: sum of 2 quarters · filed 2025-02-25 | $307.00M derived: sum of 3 quarters · filed 2025-02-25 | $392.00M 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $103.00M 10-Q · filed 2023-11-07 | $102.98M 10-Q · filed 2022-11-02 | $199.00M derived: sum of 2 quarters · filed 2023-11-07 | $284.00M 10-Q · filed 2023-11-07 | $283.90M 10-Q · filed 2022-11-02 | $357.60M derived: sum of 4 quarters · filed 2024-02-21 | ||
| 2022-06-30 | $96.00M 10-Q · filed 2023-08-07 | $95.74M 10-Q · filed 2022-08-03 | $181.00M 10-Q · filed 2023-08-07 | $180.93M 10-Q · filed 2022-08-03 | $254.60M derived: sum of 3 quarters · filed 2024-02-21 | $342.19M derived: sum of 4 quarters · filed 2024-02-21 | ||
| 2022-03-31 | $85.00M 10-Q · filed 2023-05-09 | $85.19M 10-Q · filed 2022-05-09 | $158.60M derived: sum of 2 quarters · filed 2024-02-21 | $246.19M derived: sum of 3 quarters · filed 2024-02-21 | $331.79M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2021-12-31 | $73.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $161.19M derived: sum of 2 quarters · filed 2024-02-21 | $246.79M derived: sum of 3 quarters · filed 2024-02-21 | $329.00M 10-K · filed 2024-02-21 | $328.63M 10-K · filed 2022-02-23 | |||
| 2021-09-30 | $87.60M 10-Q · filed 2022-11-02 | $173.19M derived: sum of 2 quarters · filed 2022-11-02 | $255.40M 10-Q · filed 2022-11-02 | $316.90M derived: sum of 4 quarters · filed 2022-11-02 | ||||
| 2021-06-30 | $85.60M 10-Q · filed 2022-08-03 | $167.81M 10-Q · filed 2022-08-03 | $229.30M derived: sum of 3 quarters · filed 2022-08-03 | $292.28M derived: sum of 4 quarters · filed 2022-08-03 | ||||
| 2021-03-31 | $82.21M 10-Q · filed 2022-05-09 | $143.71M derived: sum of 2 quarters · filed 2022-05-09 | $206.69M derived: sum of 3 quarters · filed 2022-05-09 | $253.81M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $61.50M 10-K · filed 2021-02-25 | $124.48M derived: sum of 2 quarters · filed 2021-11-08 | $171.60M derived: sum of 3 quarters · filed 2021-11-08 | $202.00M 10-K · filed 2023-02-28 | $201.75M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $62.98M 10-Q · filed 2021-11-08 | $110.10M derived: sum of 2 quarters · filed 2021-11-08 | $140.25M 10-Q · filed 2021-11-08 | $167.53M derived: sum of 4 quarters · filed 2021-11-08 | ||||
| 2020-06-30 | $47.13M 10-Q · filed 2021-08-05 | $77.28M 10-Q · filed 2021-08-05 | $104.55M derived: sum of 3 quarters · filed 2021-08-05 | $129.55M derived: sum of 4 quarters · filed 2021-08-05 | ||||
| 2020-03-31 | $30.15M 10-Q · filed 2021-05-05 | $57.43M derived: sum of 2 quarters · filed 2021-05-05 | $82.43M derived: sum of 3 quarters · filed 2021-05-05 | $113.34M derived: sum of 4 quarters · filed 2021-05-05 | ||||
| 2019-12-31 | $27.28M 10-K · filed 2021-02-25 | $52.28M derived: sum of 2 quarters · filed 2021-02-25 | $83.19M derived: sum of 3 quarters · filed 2021-02-25 | $103.71M 10-K · filed 2022-02-23 | ||||
| 2019-09-30 | $25.00M 10-K · filed 2021-02-25 | $55.91M derived: sum of 2 quarters · filed 2021-02-25 | $76.43M 10-Q · filed 2020-11-05 | $91.48M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $30.91M 10-K · filed 2021-02-25 | $51.43M 10-Q · filed 2020-08-06 | $66.48M derived: sum of 3 quarters · filed 2021-02-25 | $82.92M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | $20.52M 10-K · filed 2021-02-25 | $35.57M derived: sum of 2 quarters · filed 2021-02-25 | $52.01M derived: sum of 3 quarters · filed 2021-02-25 | $69.15M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | $15.05M 10-K · filed 2020-03-05 | $31.48M derived: sum of 2 quarters · filed 2020-03-05 | $48.63M derived: sum of 3 quarters · filed 2020-03-05 | $63.21M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $16.44M 10-K · filed 2020-03-05 | $33.59M derived: sum of 2 quarters · filed 2020-03-05 | $48.17M 10-Q · filed 2019-11-05 | $62.76M derived: sum of 4 quarters · filed 2020-03-05 | ||||
| 2018-06-30 | $17.15M 10-K · filed 2020-03-05 | $31.73M 10-Q · filed 2019-08-06 | $46.32M derived: sum of 3 quarters · filed 2020-03-05 | $69.62M derived: sum of 4 quarters · filed 2020-03-05 | ||||
| 2018-03-31 | $14.58M 10-K · filed 2020-03-05 | $29.18M derived: sum of 2 quarters · filed 2020-03-05 | $52.47M derived: sum of 3 quarters · filed 2020-03-05 | $62.14M derived: sum of 4 quarters · filed 2020-03-05 | ||||
| 2017-12-31 | $14.59M 10-K · filed 2019-03-05 | $37.89M derived: sum of 2 quarters · filed 2019-03-05 | $47.55M derived: sum of 3 quarters · filed 2019-03-05 | $54.85M 10-K · filed 2019-03-05 | ||||
| 2017-09-30 | $23.30M 10-K · filed 2019-03-05 | $32.96M derived: sum of 2 quarters · filed 2019-03-05 | $40.26M 10-Q · filed 2018-11-08 | |||||
| 2017-06-30 | $9.66M 10-K · filed 2019-03-05 | $16.96M 10-Q · filed 2018-08-06 | ||||||
| 2017-03-31 | $7.30M 10-K · filed 2019-03-05 | |||||||
| 2016-12-31 | $18.18M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |